Companion Diagnostics
News on companion diagnostics and drug/test co-development.
HER2 Biomarker Evolving as Enhertu Shows Activity in Breast Cancers With Ultralow Expression
Premium
The new HER2-low category is exposing the limitations of IHC testing, challenging pathologists, and has oncologists revisiting patients' old test results.
The firm presented early data for a blood-based approach to screen prostate cancer patients for PSMA, which it believes has advantages over PET imaging.
FDA Approves Roche CDx Test for Use With Jazz Pharmaceuticals Drug in Biliary Tract Cancer
The approval is for a new indication for Roche's existing Pathway HER2 (4B5) test and is intended to identify patients with HER2-positive biliary tract cancer.
Illumina to Incorporate Myriad's Genomic Instability Score Into Updated TSO 500 Cancer Assay
GIS measures DNA repair defects via loss of heterozygosity, large-scale state transition, and telomere allele imbalance.
Allarity Therapeutics Providing Biomarker Analysis Services to Biotech
The firm is now inking revenue-generating contracts with other biotech companies for its drug response prediction and gene expression analysis capabilities.